指南与共识心力衰竭与心肌病

生物标志物指导与指南指导的心衰治疗:BIOSTAT-CHF研究结果

Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF.
指南 / 共识 · J Am Coll Cardiol · 2018-01-01

BIOSTAT-CHF研究纳入2,516例恶化性心衰患者,比较三种理论治疗场景:全部上调至推荐剂量>50%、基于生物标志物选择模型上调、均不上调。在1,802例有标志物数据患者中,ACEI/ARB上调场景A、B、C的24个月死亡或住院率分别为16%、16%、26%;β受体阻滞剂为23%、19%、24%;MRA为12%、11%、24%。基于生物标志物上调可能比全部成功上调减少死亡或住院。

要点

  • 基于生物标志物选择上调治疗可能优于全部患者成功上调。
  • ACEI/ARB和MRA上调的估计事件率在生物标志物场景与全部上调场景相近或更低。
  • β受体阻滞剂生物标志物指导上调的估计事件率低于全部上调场景。

核心结论

  • 基于生物标志物值对心衰患者进行上调治疗,与假设全部患者成功上调相比,可能减少死亡或住院。

研究设计与样本

  • BIOSTAT-CHF研究,纳入2,516例恶化性心衰患者,比较三种理论治疗场景的临床结局。
  • 使用161种生物标志物及其与治疗的交互作用进行多变量Cox回归,并对治疗指征偏倚加权,估计24个月死亡或心衰住院的预期数。

主要发现

  • 在1,802例有可用(生物)标志物的患者中,ACEI/ARB上调场景A、B、C的估计死亡或住院率分别为16%、16%、26%。
  • β受体阻滞剂上调场景A、B、C的相应率分别为23%、19%、24%。
  • MRA上调场景A、B、C的相应率分别为12%、11%、24%。
  • 若全部患者成功上调,ACEI/ARB、β受体阻滞剂和MRA治疗在24个月每100例治疗患者中估计可预防9.8、1.3和12.3起事件。
  • 若基于生物标志物治疗选择模型决定上调,相应数字分别为9.9、4.7和13.1。

临床怎么用

  • 心衰治疗上调决策可考虑结合生物标志物选择,而非对所有患者一律上调至推荐剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Heart failure guidelines recommend up-titration of angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blockers (ARBs), beta-blockers, and mineralocorticoid receptor antagonists (MRAs) to doses used in randomized clinical trials, but these recommended doses are often not reached. Up-titration may, however, not be necessary in all patients. OBJECTIVES: This study sought to establish the role of blood biomarkers to determine which patients should or should not be up-titrated. METHODS: Clinical outcomes of 2,516 patients with worsening heart failure from the BIOSTAT-CHF (BIOlogy Study to Tailored Treatment in Chronic Heart Failure) were compared between 3 theoretical treatment scenarios: scenario A, in which all patients are up-titrated to >50% of recommended doses; scenario B, in which patients are up-titrated according to a biomarker-based treatment selection model; and scenario C, in which no patient is up-titrated to >50% of recommended doses. The study conducted multivariable Cox regression using 161 biomarkers and their interaction with treatment, weighted for treatment-indication bias to estimate the expected number of deaths or heart failure hospitalizations at 24 months for all 3 scenarios. RESULTS: Estimated death or hospitalization rates in 1,802 patients with available (bio)markers were 16%, 16%, and 26%, respectively, in the ACE inhibitor/ARB up-titration scenarios A, B, and C. Similar rates for beta-blocker and MRA up-titration scenarios A, B, and C were 23%, 19%, and 24%, and 12%, 11%, and 24%, respectively. If up-titration was successful in all patients, an estimated 9.8, 1.3, and 12.3 events per 100 treated patients could be prevented at 24 months by ACE inhibitor/ARB, beta-blocker, and MRA therapy, respectively. Similar numbers were 9.9, 4.7, and 13.1 if up-titration treatment decision was based on a biomarker-based treatment selection model. CONCLUSIONS: Up-titrating patients with heart failure based on biomarker values might have resulted in fewer deaths or hospitalizations compared with a hypothetical scenario in which all patients were successfully up-titrated.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Ouwerkerk W, Zwinderman AH, Ng LL, et al. Biomarker-Guided Versus Guideline-Based Treatment of Patients With Heart Failure: Results From BIOSTAT-CHF. J Am Coll Cardiol. 2018. PMID: 29389354. doi:10.1016/j.jacc.2017.11.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。